Reduction in overall infections seen within the first week, with 100% prevention of symptomatic infections.
Markedly decreased levels and duration of viral shedding in asymptomatic infections that still occurred in REGEN-COV group.
Confirmatory Phase 3 results expected early in the second quarter.
Potential application in people who need immediate protection or respond poorly to vaccination.
Check out the full article right here.